Bolt Biotherapeutics dips after cancer therapy trial delay

Bolt Biotherapeutics

02/10/2025 11:34

** Shares of drug developer Bolt Biotherapeutics BOLT.O fall 13.6% to $4.89 premarket

** Co said on Wednesday it is modifying the design of its early-stage trial for cancer drug BDC-4182, and now expects to release initial data in the third quarter of 2026

** The updated protocol will include step-up dosing, a method used in similar therapies to help reduce side effects, co said

** Co is also cutting about 50% of its workforce to extend its cash runway into 2027

** As of last close, stock down 47% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))